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Mental disorders have a high prevalence compared with many other health conditions 
and are the leading cause of disability worldwide. Several studies performed in the last 
years support the involvement of the endocannabinoid system in the etiopathogenesis of 
different mental disorders. The present review will summarize the latest information on 
the role of the endocannabinoid system in psychiatric disorders, specifically depression, 
anxiety, and schizophrenia. We will focus on the findings from human brain studies 
regarding alterations in endocannabinoid levels, cannabinoid receptors and 
endocannabinoid metabolizing enzymes in patients suffering mental disorders.  
Studies carried out in humans have consistently demonstrated that the endocannabinoid 
system is fundamental for emotional homeostasis and cognitive function. Thus, 
deregulation of the different elements that are part of the endocannabinoid system may 
contribute to the pathophysiology of several mental disorders. However, the results 
reported are controversial. In this sense, different alterations in gene and/or protein 
expression of CB1 receptors have been shown depending on the technical approach 
used or the brain region studied. Despite the current discrepancies regarding 
cannabinoid receptors changes in depression and schizophrenia, present findings point 
to the endocannabinoid system as a pivotal neuromodulatory pathway relevant in the 
pathophysiology of mental disorders. 
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Mental disorders are responsible for the largest proportion of the global burden of 
disease worldwide. It has been suggested that by 2030 depression will be the leading 
cause of disease burden globally. In this way, mood-related disorders contribute most of 
the non-fatal burden of mental illness followed by anxiety-related disorders, substance 
abuse and schizophrenia [1]. They present a major medical, societal and economic 
burden that has a large impact on individuals, families and communities. 
Actual knowledge about the etiology and pathophysiology of mental disorders is mainly 
a result of an interaction between the development of new technology and the direct 
study of the brain tissue of patients. Thus, the description of morphological differences, 
functional deficits and molecular alterations is widely accepted today as existing in the 
brain of psychiatric patients due to the advance of in vivo neuroimaging techniques, 
genetic and genomic development, and the use of postmortem brain tissue as a key 
substrate of the disease [2]. Nevertheless, despite the huge economic and scientific 
effort developed in the last decades, the pathophysiology of mental disorders remains 
elusive. In this context, many studies have focused in the possible involvement of 
alterations of the endocannabinoid system (ECS) in the pathophysiology of mental 
disorders such as depression or schizophrenia. The ECS participate, in part, in the 
control of emotional behavior and mood through a functional coupling with 
monoaminergic systems in the brain [3]. These functional interactions have suggested a 
potential role for ECS signaling in the neurobiology of various psychiatric disorders [4-
7]. The ECS is composed of two inhibitory G-protein coupled receptors (GPCRs), 
cannabinoid receptor 1 and 2 (CB1 and CB2, respectively), and two major endogenous 
ligands, N-arachidonoylethanolamine (anandamide/AEA) and 2-arachidonoylglycerol 




hydrolase (FAAH) and the monoacylglycerol lipase (MAGL) which hydrolyze AEA 
and 2-AG, respectively; and two main synthetizing enzymes, N-
acylphosphatidylethanolamine-phospholipase D (NAPE-PLD) and the diacylglycerol 
lipase (DAGL) which synthesize AEA and 2-AG, respectively. The correct interplay 
between all these ECS elements plays an important role in central nervous system 
(CNS) development, synaptic plasticity, and the homeostatic maintenance of cognitive, 
behavioral, emotional, developmental, and physiological processes [8, 9]. In the brain, 
CB1 receptors are present in GABAergic and glutamatergic neurons, exerting a 
presynaptic inhibitory function when they are activated by the released 
endocannabinoids [10, 11]. They are the most abundant G-protein coupled receptors and 
are widely expressed all throughout the brain, being located in cortical, subcortical, 
cerebellar and brainstem structures [8]. The CB2 receptors are less numerous and were 
initially thought to be located mainly in the immune system; however, currently they 
seem to present a wider distribution in the CNS, taking part in immune-mediated 
responses and supporting a neuroprotective role against inflammation [12]. The two 
main endogenous ligands, AEA and 2-AG, are eicosanoid neuromodulatory lipids 
derived from membrane phospholipids, synthesized when and where they are required, 
and acting presynaptically on both type of cannabinoid receptors [8]. 
In the present review, we will summarize data obtained from human studies providing 
evidence about the role of the different ECS components (endocannabinoids, 
metabolizing/synthetizing enzymes and cannabinoid receptors) in the pathophysiology 
and treatment of several psychiatric disorders, with a focus on results from postmortem 
and living human brain studies. We will review findings from patients suffering a 
mood-related disorder (depression, anxiety, posttraumatic stress disorder (PTSD)) or 





2. The endocannabinoid system and the emotional homeostasis  
The ECS influences the activity of multiple brain areas involved in the regulation of the 
hypothalamic-pituitary-adrenal system, mood, anxiety and other related behaviors (i.e. 
extinction of fear learning, reward…). Indeed, the ECS enables the efficient interaction 
within and between brain regions that modulate cognitive and behavioral functioning. 
A considerable number of studies suggest the relationship between changes in one or 
more components of the ECS and some of the symptoms that are present in depression 
and anxiety-related disorders. The ECS modulates fear and anxiety-related behaviors in 
both humans and rodents [13-15]. Augmented ECS signaling is usually followed by 
reduced conditioned fear and anxiety, whereas the opposite effect is observed when it is 
inhibited [16-19]. This is not surprising since the ECS is present in key structures within 
the brain such as prefrontal cortex (PFC), amygdala, and hippocampus [20-25].  
There are also animal studies showing the correlation between CB1 receptor-deficiency 
and depressive/comorbid symptoms (anhedonia, anxiety, and heightened stress-
response) [26-28]. In line with this relationship, chronic stress, as a pathogenic factor 
for depressive-behavior, has been associated with a dysfunctional endocannabinoid 
signaling in the brain [29]. Thus, strategies that are directed to the augmentation of the 
endocannabinoid signaling are reported to mitigate many of the adverse effects of 
chronic stress, such as anhedonia and anxiety [30-32]. The readers are directed to 
comprehensive reviews on this topic that is beyond the scope of this review [33-38]. 
3. The endocannabinoid system and depression  
Depression is one of the most prevalent major neuropsychiatric diseases, affecting 20% 




two main challenges to fight against depression. First, we still poorly understand its 
neurobiological and pathological bases. Second, there needs to be more effective 
antidepressant drugs overcoming the therapeutic lag between drug administration and 
the onset of clinical improvement, the lack of response in some patients and 
safety/tolerability issues [40, 41]. 
The implication of the ECS in depression comes from observational findings regarding 
the mood-related effects of cannabis in humans, though contradictory results are 
reported. On the one hand, the heavy use of cannabis is associated to a higher incidence 
of depressive disorders [42]. A recent meta-analysis showed a positive correlation 
between cannabis use and depression, more evident among heavy cannabis users [43]. 
Moreover, the abuse of cannabis has been linked to a higher risk of suicide in patients 
with mood disorders[44]. On contrast, other authors indicate that the use of marijuana, 
or its main component ∆9-tetrahidrocannabinol (THC), reduces the depressive behavior 
[45-48]. In addition, other authors describe that the administration of THC to patients 
with moderate to severe depression shows a lack of effect on mood [49], or on the 
suicidal ideation [50], but an increased anxiety [49]. 
Curiously, the pharmacological blockade of CB1 receptors using antagonists or inverse 
agonists was initially suggested as a potential novel target for antidepressant treatment, 
according to different evidences in preclinical studies [51]. However, further studies 
revealed that drugs as the CB1 receptor antagonist rimonabant (SR 141716A) that was 
marketed to treat obesity, induced depressed mood [52, 53]. In animal studies, the 
pharmacological activation or blockade of CB1 receptors also give rise to contradictory 
results, since both approaches lead to an antidepressant-like effect [5, 51, 54-58]. 
Although these studies draw conflicting findings, they point to the involvement of the 




to major depression have received particular attention [59]. The activation of 
cannabinoid receptors produces the release of stress hormones as ACTH and cortisol in 
the hypothalamic-pituitary-adrenal (HPA) axis [60], which has been observed following 
acute marijuana administration [61]. However, this presents tolerance after chronic 
administration [62], as the THC-induced cortisol release is blunted in frequent 
marijuana users [63]. 
Neuroimaging studies in non-cannabis users show that the administration of THC 
produces a reduced activation of some brain areas in response to a negative content [64, 
65]. Conversely, there is an increased activation in response to a positive content, 
mediated by the activation of areas as prefrontal and occipital cortices, amygdala, 
hippocampus and orbitofrontal gyrus [65], which is associated to a reduction in the 
negative attentional bias, and the potentiation of positive attentional bias [65]. This type 
of studies have also shown that the activation of cannabinoid receptors leads to 
morphological changes, as the reduction in white matter (WM) observed in marijuana 
users that negatively correlate with the severity of the depressive disorder [66, 67]. This 
decrease in WM volume has been associated with the presence of cannabinoid receptor 
in oligodendrocytes, the myelin-forming cells [68]. 
 
3.1 Cannabinoid receptors in depression 
Human studies have corroborated the existence of an altered ECS activity associated to 
major depression [34, 69]. The CB1 receptor density [70] and mRNA [71] is increased 
in the dorsolateral prefrontal cortex of patients with major depression, in parallel to CB1 
receptor functionality (evaluated by [35S]GTPγS binding studies) [70]  Mato et al., in 
this issue. However, no changes in CB1 immunoreactivity in the dorsolateral prefrontal 




cingulate cortex [73] have been reported (Table 1). Regarding the CB2 receptor, no 
changes have been detected in its mRNA levels in prefrontal cortex of depressed 
patients [71] (Table 1). 
The role of the ECS in the effect of antidepressant drugs has also been evidenced in 
studies reporting an increased CB1 receptor expression  [74], and a lack of changes in 
CB1-mediated activation of Gi/o proteins in prefrontal cortex (Mato et al., in this issue) 
in the antidepressant-treated group. Other areas as the hippocampus only elicited 
increased CB1 receptor density after chronic monoamine oxidase inhibitors (MAOI) 
treatment [74]. On contrast, studies in human brain samples have shown a reduction in 
CB1 receptor immunoreactivity in the anterior cingulate cortex of patients treated with 
serotonin selective reuptake inhibitors (SSRIs) [73]. 
The presence of different single nucleotide polymorphisms in the cannabinoid receptor 
1 (CNR1) gene appears to modulate either the depressive phenotype, and/or the 
response to antidepressant treatment. The carriers of CNR1 gene variants influences the 
vulnerability to suffer mental disorders, including major depression [75]. The frequency 
of the G allele of the CNR1 gene polymorphism rs806371 is higher in patients with 
major depression showing comorbid psychotic symptoms, while the haplotype C-G-T 
(rs806368, rs1049353, rs806371) is associated with an increased risk for melancholic 
and psychotic symptoms of major depression [76]. This is consistent with the 
melancholic depressive-like symptoms observed in animal models with 
pharmacological or genetic blockade of the ECS [4]. Other studies report a lower 
incidence of depression in Parkinsons’ disease patients carrying two long alleles of the 
CNR1 gene polymorphism (AAT)n [77]. The C allele carriers of the CNR1 gene 
polymorphism rs2023239 present a lower incidence of major depression within a group 




In patients with the CNR1 gene polymorphism rs1049353, carriers of one or more 
copies of the minor allele (AA/AG) exhibit a buffering effect to anhedonia and 
depression after early childhood trauma [79]. Moreover, the G allele of the rs1049353 
polymorphism is associated to the resistance to the antidepressant treatment in females 
diagnosed with major depression that present comorbid anxiety [80]. Patients with the G 
allele of the CNR1 rs1049353 also present a subcortical hypo-responsiveness in the 
bilateral amygdala, putamen, and pallidum activity and left lateralized caudate and 
thalamus activity, to specific cues, which might be linked to a deficient effect on the 
processing of emotional and social behavior [80]. On contrast, other authors report a 
better response to treatment of male presenting the GG genotype [76]. In patients treated 
with citalopram, TT homozygous carriers for the rs806368 and rs806371 
polymorphisms, show a higher incidence of no remission, compared to the G carriers 
[76]. Moreover, the response in the rs806368 G carriers was different depending on the 
gender, presenting a better antidepressant outcome in men than in women [76]. 
Although the CB2 receptor subtype is less abundant than CB1 receptor subtype in brain, 
some studies describe also an association with mental disorders. In this sense, the RR 
genotype of the Q63R polymorphism in the CNR2 gene present a higher association 
with depression in the Japanese population [81]. This Q63R polymorphism presents 
also a high incidence in patients with eating disorders (anorexia nervosa and bulimia 
nervosa) [82] and schizophrenia [83]. Studies in cells expressing this mutated form of 
the CNR2 gene showed that the functional relevance of this polymorphism is due to 
changes in CB2 ligand affinity, constitutive activity and a reduced 2-AG-induced 
adenylyl cyclase inhibition [84]. In the CNR2 gene polymorphism rs2501431, the AA 




The activity of cannabinoid receptors is associated to the cross-regulation that the CB1 
receptors exert over the NMDA receptors mediated by their interaction via the histidine 
triad nucleotide binding protein 1 (HINT-1), in which a reduction in the number of CB1 
receptors may be associated to the NMDA hyperfunction observed in depression [86]. 
In this sense, molecular studies have shown an increase in the HINT-1 protein and the 
NR1 subunit of the NMDA receptors in the prefrontal cortex of depressed patients, in 
parallel to results obtained in CB1 receptor knockout mice [86]. 
 
3.2 Endocannabinoid metabolizing enzymes in depression 
One of the most frequent polymorphism of FAAH in humans is a functional non-
synonymous single-nucleotide polymorphism (C385A; rs324420) associated with a 
reduced cellular expression of this enzyme. The C385A polymorphism of the FAAH 
gene, presents a greater association in A allele carriers with pathologies as depression 
and bipolar disorder [87]. Moreover, the presence of this polymorphism constitutes a 
susceptibility factor to develop depressive and anxious phenotypes in adult individuals 
that have been exposed to childhood trauma [88]. The high AEA levels because the 
reduced FAAH activity in the A allele carriers, induce the desensitization of CB1 
receptors. This reduction in CB1 receptors promotes a glutamatergic hyperactivity that, 
together with high cortisol levels due to childhood trauma in critic neurodevelopmental 
periods, results in anxious and/or depressive disorders [88]. The CC carriers of the 
rs324420polymorphism in the FAAH gene present a reduction in the WM integrity of 
fibers that connect with the anterior cingulate cortex and the orbital cortex, and greater 





3.3 Endocannabinoids levels in depression 
The serum content of endocannabinoids is also altered in major depression. Some 
authors report lower levels of the circulating endocannabinoids AEA and 2-AG in 
patients with depression [89, 90]. Moreover, the 2-AG levels are lower in patients with 
a longer duration of the depressive episode, while patients with minor depression 
present higher levels of AEA [89]. On contrast, other authors report no changes in AEA 
and 2-AG levels in depressed women [91]. 
The levels of the endocannabinoids AEA and 2-AG were not modified in response to 
SSRIs as fluoxetine, while the chronic administration of MAOIs induced a reduction in 
areas as prefrontal cortex, hippocampus and hypothalamus [74]. These data are 
consistent with a study that associate the beneficial effect of exercise in depression with 
an increase in the plasma levels of AEA, BDNF and cortisol [92]. 
 
4. The endocannabinoid system and anxiety-related disorders  
Few neurochemical, molecular genetics and neuroimaging studies suggest a potential 
link between dysregulation of the endocannabinoid signaling and anxiety-related 
behavior in both healthy and patients with mental disorders in which anxiety is a core 
symptom (PTSD, social phobia, agoraphobia, etc…). 
 
4.1 Cannabinoid receptors in anxiety 
Two single nucleotide polymorphism (SNP) variants (C-A and C-G) of the haplotype 
formed by the polymorphisms rs806368 and rs1049353 at the CNR1 gene showed a 
significant association with PTSD [93]. Moreover, a higher risk to suffer anxiety is 




HTTLPR) in the SLC6A4 promoter is combined with the homozygous ’GG’ rs2180619 
of CNR1 gene [94]. This highlight the strong interaction between the serotonergic 
system and the ECS on anxiety disorders as extensively described in many preclinical 
and clinical studies, using pharmacological and genetic approaches [37, 95, 96]. 
Moreover, Heitland et al. [97] published the first evidence, in healthy medication-free 
human subjects, of the implication of ECS in the fear extinction phenomenon, a relevant 
mechanism underlying the pathophysiology of human anxiety disorders. These authors 
describe the effect of the CNR1 gene polymorphism rs2180619 in the response to fear 
conditioning and extinction. They found that both homozygote (G/G) and heterozygote 
(A/G) G-allele carriers of this polymorphism showed a clear extinction of fear, whereas 
this response was absent in homozygotes (A/A). 
Recent findings suggest that during childhood and adolescence, the ECS is critical to 
mediate a correct balance between excitatory and inhibitory neurotransmission, 
especially within the prefrontal cortex [98]. This makes the endocannabinoid signaling 
quite sensitive for developmental fluctuations due to environmental causes, which may 
increase the risk of anxiety and other stress-related disorders. Interestingly, a recent 
study show the impact of the variation in the CNR1, CNR2, and FAAH genes in a 
sample of children with a primary anxiety disorder diagnosis [99]. These authors nicely 
reported an association between two SNPs (rs12133557 and rs6454676) in the CNR1 
gene and the change in symptom severity in both the entire sample and a subset of 
patients with fear based diagnoses [99]. Moreover, a favorable and a poorer response 
during the active treatment period were associated with minor allele of rs12133557 and 
rs6454676, respectively. Regarding the CNR2 gene, unlike to previous findings in 
depression [81], the rs2501431 genotype was not associated with anxiety symptoms or 




In vivo neuroimaging studies also support the existence of an abnormal CB1 receptor-
mediated signaling specially in PTSD. Using positron emission tomography (PET) with 
[11C]OMAR, as a CB1-selective tracer, Neumeister and colleagues [100] reported a 
higher CB1 receptor availability in untreated individuals with PTSD, relative to control 
subjects (with or without lifetime histories of trauma), which was most pronounced in 
women. This up-regulation of CB1 receptors was present in anxiety-related brain areas, 
especially the amygdala-hippocampal-cortico-striatal neural circuit. In a later report, the 
same group [101] assessed the attentional bias to threat, which is considered one of the 
main endophenotypic characteristics of trauma-related mental disorders. In line with 
their previous findings, they reported a positive correlation between an increased CB1 
receptor availability ([11C]OMAR binding) in the amygdala and increased in both 
attentional bias to threat and the severity of threat. Interestingly, this greater CB1 
receptor availability in the amygdala was associated with lower plasma levels of AEA. 
 
4.2 Endocannabinoid metabolizing enzymes in anxiety 
Pharmacological strategies that reduce the activity of either FAAH or MAGL have been 
reported to reduce anxiety-like behaviors in rodents and humans [37]; however, dual 
FAAH/MAGL inhibitors did not reduce stress-related affective dysfunction regardless 
of treatment timing [102]. There are several studies linking the activity of FAAH, 
especially in the amygdala, with stress-reactivity and risk to suffer anxiety-disorders.  
In healthy volunteers, there are some studies examining the impact of the FAAH gene 
polymorphism C385A (rs324420) on threat- and reward-related human brain function. 
Using imaging genetics, a decreased threat-related amygdala reactivity but increased 
reward-related ventral striatal reactivity was detected in carriers of the A allele of the 




to threat and lower scores on the personality trait of stress-reactivity was found to be 
associated with carriers of a low-expressing FAAH variant (385A allele; rs324420) 
[104]. More recently, an enhanced fear extinction was demonstrated in both mouse and 
human A-allele carriers of this FAAH gene C385A polymorphism, highlighting again 
the association of the increased fronto-amygdala connectivity with enhanced stress-
reactivity [105]. This genetic alteration appears to have functional consequences since a 
markedly reduced FAAH protein expression was detected in many cortico-limbic areas 
using the first available positron emission tomography (PET) radiotracer ([11C]CURB) 
in human brain [106]. Regarding the role of FAAH on PTSD, Pardini et al. [107] 
reported an association of the rs2295633 SNP of FAAH gene with PTSD diagnosis in 
male Vietnam War veterans without lesions in the ventromedial prefrontal cortex. Even 
more, the C allele was present in subjects that had a more negative reported experience 
of trauma (Table 1). 
 
4.3 Endocannabinoid levels in anxiety 
Preclinical findings suggest that the pharmacological manipulation of endogenous either 
AEA or 2-AG levels under stressful conditions could represent a good strategy for 
treatment of anxiety-related disorders [108]. Thus, it is plausible to hypothesize the 
existence of altered endocannabinoid levels in the brain of patients diagnosed of 
psychiatric diseases in which anxiety is either core or a comorbid symptom. 
Decreased plasma AEA levels are found in PTSD patients relative to healthy control 
subjects without trauma history [109], though elevations are also reported in chronic 
PTSD [110]. The AEA deficiency seems to be specific of PTSD patients since healthy 
subjects with lifetime histories of trauma, but without PTSD, exhibit normal AEA 




levels of AEA and increased CB1 receptor availability in the amygdala has been 
reported; in addition, AEA levels were negatively associated with attentional bias to 
threat [101]. Intriguingly, this inverse relationship between AEA levels and anxiety 
appears to be disease-specific since acute stress increases the circulating levels of AEA 
and others endocannabinoids, in parallel with cortisol [111]. Regarding the 2-AG, 
reduced [112] and increased [110] levels among individuals meeting diagnostic criteria 
for PTSD were described. Healthy humans that were subjected to prolonged stress (520-
day isolation period and simulating a flight to Mars) showed reduced blood levels of 2-
AG, but not AEA [113]. 
All these findings suggest the interaction between the ECS and HPA axis activity in 
response to stress, especially at the level of the amygdala [19]. In line with this 
relationship, a recent imaging genetics study [114] revealed a molecular interaction 
between genetic polymorphisms associated with differential AEA (FAAH rs324420) 
and corticotrophin releasing hormone (corticotropin-releasing hormone receptor 1, 
CRHR1 rs110402) signaling and amygdala function. However, in a very recent study, 
the levels of circulating endocannabinoids were measured in subjects with and without 
history of psychiatric disorder and the relationships with categorically DSM-5 defined 
disorders or state dimensional measures of depression or anxiety were studied. 
Surprisingly, neither AEA nor 2-AG levels differed as a function of any 
syndromal/personality disorder and neither correlated significantly with state depression 
or state anxiety scores [115]. Therefore, we must be cautious since peripheral 
endocannabinoid levels may be not well correlated with brain concentrations. 
 




Schizophrenia is one of the main psychiatric syndromes together with Major 
Depression. It is a chronic and devastating disorder affecting 1% of the population 
worldwide. Individuals diagnosed with schizophrenia have impaired social and 
occupational functioning. Thus, the combined economic and social costs of 
schizophrenia place it as the world’s 15th cause of disease-related disability [116]. The 
clinical features of schizophrenia are clustered in positive symptoms (i.e. hallucinations 
and delusions); negative symptoms (i.e. social withdrawal and blunted affect) and 
cognitive deficits (i.e. impaired working memory and cognitive flexibility). Current 
antipsychotic drugs, which are the main treatment for schizophrenia, are not effective in 
all patients and its benefits are restricted to the amelioration of the positive symptoms, 
having none or limited impact in negative symptoms and cognitive impairment.  
Despite the efforts of the scientific community in the last decades to elucidate the 
etiological basis of schizophrenia, the etiopathogenesis of the disease remains unknown. 
Since many years, the predominant focus of studies concerning the biological substrates 
of schizophrenia has been primarily centered on unique neurotransmitters including 
dopamine, serotonin, glutamate and γ-aminobutyric acid (GABA). Nonetheless, the 
limited efficacy of current antipsychotic drugs to treat some of the symptoms of 
schizophrenia has lead up researchers to investigate other potential neurotransmitter 
systems that may be altered in this disease.  
In this sense, the ECS has become a hot-topic in schizophrenia research in the last years. 
Several studies starting from the 40s up to nowadays agree that the ECS represents a 
major neuromodulatory system participating in tones of physiological processes [117, 
118]. Thereby, deregulation of the ECS has been speculated to be a proximal pathology 
in some forms of schizophrenia. In this sense, two ‘cannabinoid hypotheses’ of 




that deregulation of the ECS may contribute to the pathophysiology of schizophrenia, 
whereas the exogenous theory refers to the risk associated with cannabis abuse that 
could facilitate the onset of the disease in vulnerable individuals or aggravate the 
symptoms in schizophrenic patients. The psychotomimetic effects of cannabis plant are 
known since thousands of years, but the first systematic work concerning psychotic-like 
experiences after acute cannabis use came in the 19th century, by Jacques-Joseph 
Moreau [120]. In his book he described a plethora of symptoms resembling those of 
schizophrenia, including delusions, disorganized speech, and other psychotic symptoms. 
The high expression of CB1 receptors in the central nervous system, as well as the 
discovery that the psychoactive compound of cannabis THC actually binds to this 
receptor in the brain, seem sufficient reasons to consider this system an interesting field 
of study in the context of psychiatric diseases, such as schizophrenia.  
In this sense, different publications have reported alterations of the ECS components in 
the brain of patients with schizophrenia. The evidence for the implication of different 
elements of the central ECS in the pathophysiology and treatment of this psychiatric 
disorder are presented below. 
 
5.1 Cannabinoid receptors in schizophrenia 
Several studies have investigated the status of CB1 receptors in the brain of patients 
with schizophrenia. Both, imaging and postmortem brain studies have reported 
alterations on CB1 receptor availability, density and/or mRNA expression but with 
different outcomes. Thus, the integration of these results seem to be complex and 




Three neuroimaging PET studies have evaluated the CB1 receptor availability in 
schizophrenic patients compared to controls [121-123]. The first two studies, by Wong 
et al. [121] and Ceccarini et al., [122] reported a generalized increase in CB1 receptor 
density in most brain regions of schizophrenic patients compared to controls, being 
statistically significant only in certain areas (Table 2). Interestingly, these studies also 
reported that CB1 receptor binding in certain areas correlated with the severity of 
positive symptoms and inversely correlated with the severity of negative symptoms 
[121, 122]. Opposite to these first reported imaging findings, a recent PET study by 
Ranganathan et al. [123], showed a significant decrease in CB1 receptor availability in 
patients with schizophrenia compared to healthy controls (Table 2). Moreover, this 
study showed a positive global association between both positive and negative 
symptoms and the availability of CB1 receptors in schizophrenia [104]. Given these 
discordant findings related to CB1 receptor availability in schizophrenia and its 
association with different symptoms of the disease, the necessity of further in vivo 
assessments in this regard becomes clear. Explanations for the contradictory results 
reported in imaging studies published so far, have been discussed in detail [124]. Thus, 
confounding factors such as sex and age of patients and controls included in the studies, 
the radiotracers and the procedures used for the analysis, the influence of cannabis 
and/or tobacco consumption and the impact of antipsychotic medication have been 
proposed as variables that can account for the discrepancies of these results [124].  
Regarding postmortem studies in the brain of patients with schizophrenia, also different 
outcomes for gene and/or protein expression of CB1 receptors have been shown 
depending on the technical approach used. Thus, different reports have linked 
schizophrenia with increased, decreased or unaltered expression/density of CB1 




consistently reported increased density of CB1 receptors in schizophrenia [125-131]. 
Six out of the eight radioligand binding studies published to date have reported an 
increase of CB1 receptor density in the brain of schizophrenic subjects compared to 
controls in areas known to be involved in schizophrenia, including the cingulate cortex 
and dorsolateral prefrontal cortex (Table 2). The only study that has evaluated CB1 
receptor binding density in the superior temporal gyrus, a brain area particularly 
involved in auditory hallucinations [132], found no differences between schizophrenic 
subjects and controls [128]. This fact, could suggest that the alterations found in CB1 
receptor density in schizophrenia might be more associated to negative and/or cognitive 
symptoms of the disorder, which are linked with altered cortical functions integrated by 
the cingulate cortex (emotional processing and selective attention responses) and the 
dorsolateral prefrontal cortex (DLPC) (motivational responses and executive functions) 
[133]. Interestingly, the study by Dalton et al. [129] only found increased CB1 receptor 
binding in the DLPC of schizophrenic patients with a diagnosis of paranoid 
schizophrenia, characterized by the presence of prominent delusions or hallucinations, 
while no changes were reported in non-paranoid schizophrenic patients, indicating that 
also the type of diagnoses can influence the outcomes obtained. This fact highlights the 
relevance of the source of the diagnoses and the potential influence of changes in the 
clustering of schizophrenia spectrum disorders in the diagnosis manuals along time. 
One example of these changes, is the modification in schizophrenia definition in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition [134], 
respect to the previous one, that eliminates the clustering of schizophrenia classic 
subtypes —disorganized (hebephrenic), catatonic, paranoid, and undifferentiated— 
adding psychopathological dimensions instead [135]. This decision was made because 




heterogeneity of schizophrenia, low diagnostic stability, do not exhibit distinctive 
patterns of treatment response or longitudinal course, and are not heritable [135]. Thus, 
the comparisons of the outcomes between different schizophrenia subtypes should be 
interpreted with caution. 
The potential influence of antipsychotic medication in CB1 receptor radioligand binding 
studies has been also taken into account. These reports state that the increases in CB1 
receptor density were not related to the antipsychotic treatment given to the patients 
[125-127, 129-131]. However, it must be noticed that in all the studies more than 80% 
of schizophrenic subjects included were under antipsychotic medication at the time of 
death. The evaluation of the impact of antipsychotic drugs on CB1 receptors in 
schizophrenia postmortem studies is difficult to overcome due to the lack of brain tissue 
from drug naïve patients. Nevertheless, the inclusion of a greater number of 
schizophrenic patients with a negative toxicology for antipsychotics at the time of death 
could provide new information in this regard when compared with antipsychotic-treated 
patients. 
Opposite to radioligand binding studies, CB1 receptor immunoreactivity has been found 
to be decreased in the postmortem DLPC of schizophrenic subjects compared to 
controls, with or without changes in CB1 receptor mRNA [72, 136, 137] (Table 2). 
Urigüen et al. [137] reported a significant decrease in CB1 receptor immunoreactivity 
only in the DLPC of schizophrenic subjects that were antipsychotic-treated at the time 
of death without changes in those with a negative toxicology for antipsychotics. In the 
two reports by Eggan et al. [72, 136] decreased CB1 receptor immunoreactivity was 
shown in the DLPC of subjects with schizophrenia compared to controls. Authors 
argued that this decrease was not a consequence of the antipsychotic treatment based on 




presence of antipsychotic medication, and on the absence of alterations in CB1 
expression in the brain of antipsychotic treated monkeys [72, 136]. However, more than 
75% of the schizophrenic subjects included in these studies were positive for 
antipsychotic drugs at the time of death, making it difficult to find statistical 
significance when assessing the potential impact of antipsychotics. CB1 mRNA 
expression has also been shown decreased in the DLPC of schizophrenic subjects [136], 
although absence of changes have also been reported [137]. In the cingulate cortex, no 
alterations in CB1 receptor immunoreactivity nor CB1 receptor mRNA have been found 
[73] (Table 2). The reported changes in CB1 receptor inmunoreactivity in the DLPC of 
medicated schizophrenic subjects point to a role of the antipsychotic treatment in the 
regulation of the ECS in this brain area. However, it is unknown whether this 
antipsychotic modulation of CB1 receptors could contribute or not to the therapeutic 
effects of these drugs. Taking into account all the results form postmortem studies 
regarding CB1 receptors in schizophrenia, showing lower or unchanged levels of 
mRNA, reduced immunoreactivity and higher receptor binding, two potential 
hypotheses have been proposed: 1) an altered trafficking of the receptor resulting in 
higher levels of membrane-bound CB1 receptor, and 2) a higher CB1 receptor affinity 
[131]. Both situations would entail a greater CB1 receptor availability, something that is 
not supported in all the neuroimaging studies reported to date [123]. 
Overall, the imaging and postmortem outcomes regarding CB1 receptor availability, 
density and expression in the brain of schizophrenic patients, although inconclusive, 
point towards a role of CB1 receptors in this pathology. Further research including 
functional assessment of the status of this receptor might help in understanding the 
potential pathophysiological consequences of the altered CB1 receptor availability, 




Little is yet known about the status of CB2 receptors in schizophrenia. To date, the only 
study reporting data related to CB2 receptor in the brain of schizophrenic patients found 
no significant correlation between the diagnosis of schizophrenia and total CB2 mRNA 
expression in the postmortem DLPC (BA9) [82] (Table 2). The main goal of this study 
was to test the association between tag SNPs in the CNR2 gene and schizophrenia. In 
this regard, authors showed two SNPs associated with schizophrenia that were also 
related to reduced function of CB2 receptors, thus concluding that people with 
genetically predetermined lower functioning of CB2 receptors has an increased 
susceptibility to suffer schizophrenia when combined with other risk factors[82]. 
Previously, in 2003, De Marchi and co-workers [138] reported that clinical remission in 
schizophrenic patients was accompanied by a significant decrease in CB2 receptor 
mRNA in peripheral blood mononuclear cells. This finding does not agree with the 
observations of potential reduced CB2 receptor function associated with increased risk 
for schizophrenia [82], but authors also suggested that these peripheral changes might 
be related to several immunological alterations described in this pathology [138]. 
Nevertheless, further research is needed to support the potential role of CB2 receptors in 
schizophrenia. 
Several genetic studies investigating different components of the ECS in patients with 
schizophrenia have been carried out, most of them focusing on different polymorphisms 
of the CNR1 gene. Nevertheless, it must be noted that all genetic studies have been 
carried out in peripheral blood samples, and not in the brain. As these studies goes 
beyond the main scope of this review, only a brief summary of the studies will be 
provided. 
Nineteen studies have addressed different CNR1 polymorphisms in relation with 




when comparing with the general population of schizophrenic patients from different 
genetic backgrounds [139-142]. Another study from Seifert et al. studied two other 
SNPs apart from the triplet AAT (rs6454674 and rs1049353), not finding any 
association with any of them [143]. Nevertheless, a nine-time repetition of the triplet 
AAT in CNR1 has been associated with the hebephrenic subtype of schizophrenia in 
two different studies, carried out in Caucasian and Japanese population [144, 145]. 
Ujike et al. [144] also addressed the association of rs1049353 in their cohort, but, as in 
the study of Seifert, they did not find any linkage. These data reflect the heterogeneity 
of the schizophrenia and suggest that variations in the CNR1 gene may contribute to the 
pathogenesis of specific subtypes of this disorder. 
Some other studies have analyzed the SNP rs1049353 in schizophrenic patients [87, 
146], none of them showing any significant linkage. Several other studies have failed in 
trying to find associations between different SNPs of CNR1 (rs806366, rs806368, 
rs806376, rs806379, rs806380, rs6454674, sr1535255 among other) and schizophrenia 
[147-150]. However, some SNPs such as rs6454674 [151], rs2023239 [152] and 
interactions with rs1049353, rs1535255, and rs2023239 [152] have been associated with 
positive and negative symptoms. At the same time, a study from Tiwari et al. have 
found an association between CNR1 SNP rs806378 and the weight gain as a 
consequence of antipsychotic treatment [153].  
An interesting study evaluated interactions between CNR1 gene polymorphisms, 
cannabis use, cerebral volume and cognitive function [154]. They compared patients 
with schizophrenia or schizoaffective disorder with cannabis abuse/dependency and 
patients without cannabis use and observed smaller frontotemporal white matter (WM) 
volumes in those that smoked cannabis. They also observed associations between SNPs 




rs12720071 and processing speed/attention and problem-solving tests. Those results 
suggest that the use of cannabis in association with specific CNR1 genotypes can 
contribute to alterations in WM and cognitive deficits in a subgroup of schizophrenic 
patients, which supports the hypothesis that both genetic and environmental factors 
could work together to determine the phenotypic expression in patients with 
schizophrenia. 
Regarding genetic studies involving CNR2, data are critically scarce. One study has 
reported a close relationship between a polymorphism of the CNR2 and increased 
susceptibility to schizophrenia in a large Japanese population [83]. This association was 
also confirmed in postmortem PFC from schizophrenic and control subjects with other 
ethnicities, being the risk allele also associated with low CB2 receptor mRNA levels 
[83]. Furthermore, culture cell experiments showed that this CNR2 gene polymorphism 
was linked to a lower functionality of the CB2 receptor, suggesting an increased risk of 
schizophrenia for people with low CB2 receptor function [83]. 
 
5.2 Endocannabinoid synthesizing and metabolizing enzymes in schizophrenia 
Only a few studies have evaluated the endocannabinoid enzymes in the brain of patients 
with schizophrenia (Table 2). In the first study [155], quantitative polymerase chain 
reaction (PCR) was used to measure mRNA levels of DAGL (DAGLα and DAGLβ), 
MAGL, and FAAH. The mRNA level quantification of these enzymes was carried out 
in the prefrontal cortex Brodmann's area 9 of 42 schizophrenia subjects and matched 
control comparison subjects. No differences between subject groups were found in 
mRNA levels for endocannabinoid synthesizing and metabolizing enzymes. 
In a more recent study, the same authors studied the transcript levels for the recently 




prefrontal cortex of schizophrenia and healthy subjects (n = 84), using quantitative PCR 
[156]. This study showed that ABHD6 mRNA levels were elevated in schizophrenia 
subjects who were younger and had a shorter illness duration relative to age-matched 
comparison subjects. Furthermore, age and illness duration were strongly correlated in 
schizophrenia subjects, which made it difficult to differentiate between their effects on 
ABHD6 mRNA levels.  
On the other hand, Morita et al. investigated a possible relationship between the non-
synonymous polymorphism in Pro129Thr (rs324420) of the FAAH gene and 
schizophrenia. No differences were found in a group of 260 patients with schizophrenia 
(127 paranoids, 127 hebephrenics and 6 not classified) as compared to 63 controls in a 
Japanese population, regardless of the disorder subtype [157].  
 
5.3 Endocannabinoid levels in schizophrenia 
To date, only one study has evaluated endocannabinoid levels directly in the brain of 
patients with schizophrenia [158]. In this postmortem study, contents of the two main 
endocannabinoids, 2-AG and AEA, as well as other endocannabinoid and 
cannabimimetic compounds were quantified in three brain regions of subjects with 
schizophrenia and matched controls. The study revealed an opposite pattern for the 
regulation of endocannabinoids in schizophrenia. Authors found increased levels of 2-
AG in cerebellum, hippocampus, and DLPC, whereas decreased levels of AEA and 
other N-acylethanolamines —dihomo-γ-linolenoylethanolamine (LEA), 
oleoylethanolamide (OEA), palmytoylethanolamide (PEA), and 
docosahexaenoylethanolamine (DHEA) — were reported [158]. In this way, 




cortex and hippocampus, but not in cerebellum, of antipsychotic-treated patients 
compared to antipsychotic-free subjects [158].  
Before this study, several works focused their attention in the link between 
endocannabinoid levels, in both cerebrospinal fluid (CSF) and blood, and schizophrenia 
[138, 159-162]. Thus, four studies of the same research group have reported elevated 
AEA levels in CSF of schizophrenic patients, with no significant differences in serum 
AEA levels between schizophrenic patients and controls [159-162]. Moreover, in non-
medicated acute schizophrenics, a negative correlation was found between CSF AEA 
levels and psychotic symptoms [160]. The increases of AEA levels reported in CSF 
from patients with schizophrenia contrast with the reduced AEA found in postmortem 
human brain of schizophrenics, but the neuronal origin of CSF endocannabinoids 
remains conjectural and it might reflect peripheral alterations of these signaling 
messengers [138]. In this sense, an increase in AEA levels in the blood of patients with 
acute schizophrenia respect to healthy volunteers has been reported [138]. Furthermore, 
in schizophrenic patients, pharmacologically-induced remission of the symptoms was 
accompanied by a significant decrease of blood AEA levels and of the mRNA 
transcripts for the degrading enzyme FAAH [138]. Thus, it has been proposed that the 
increased blood AEA levels observed in patients with acute schizophrenia might be due 
to the modified immune response observed during the course of the disease [138]. In 
fact, patients in initial prodromal states of psychosis with lower levels of AEA in CSF 
showed a higher risk for transiting to psychosis earlier [162]. Regarding the effect of 
antipsychotic medication on CSF endocannabinoid levels, AEA concentrations 
remained increased in patients that were treated with atypical antipsychotics, but not in 




In this line, a clinical trial in acute schizophrenia has evaluated the antipsychotic effects 
of the non-psychoactive phytocannabinoid cannabidiol (CBD) versus the atypical 
antipsychotic amisulpride, assessing in turn endocannabinoid serum levels along 
treatments [163]. Either treatment was safe and led to significant clinical improvement, 
but CBD displayed a markedly superior side effects profile. Results also showed that 
treatment with CBD, but not with amisulpride, was accompanied by a significant 
increase in serum AEA levels that were also associated with clinical improvement 
[163]. These authors suggest that inhibition of AEA deactivation may contribute to the 
antipsychotic effects of CBD potentially representing a completely new mechanism in 
the treatment of schizophrenia [163].  
Besides AEA, other endocannabinoids have also been evaluated in CSF or serum of 
patients with schizophrenia. There is only one study which has attempted to determine 
2-AG levels in CSF of schizophrenic patients [159]. However, despite being the most 
abundant endocannabinoid in the brain [164], significant levels of 2-AG could not be 
detected in any of the samples analyzed, suggesting that this endocannabinoids 
concentrations are exceedingly low in CSF of both controls and schizophrenic patients. 
The levels of the endogenous analogues of AEA, OEA and PEA, have also been 
explored out of the brain in schizophrenia. In observational studies, no differences were 
found in CSF or serum OEA levels between controls and schizophrenic patients [159-
162]. By contrast, a 2-fold increase in PEA CSF levels was found in schizophrenic 
patients compared to controls [159]. However, this finding was not replicated in 
subsequent studies [160, 161]. In previously mentioned clinical trial with CBD 
performed in patients with acute schizophrenia, both OEA and PEA serum levels were 
significantly elevated in schizophrenic patients treated with CBD, compared to those 




It is also noteworthy that CSF endocannabinoid levels have been shown to be affected 
depending on the history of cannabis use. Thus, markedly altered AEA concentrations 
(>10-fold higher) were reported in CSF of a subgroup of schizophrenic patients who 
had low frequency cannabis use compared to controls (with high and low frequency 
use), as well as compared to schizophrenic high-frequency users [161]. However, this 
impact of cannabis use was not observed in other studies [160, 162]. 
 Compiling the information available from these studies is evident that the relationship 
between levels of endocannabinoids measured in the CSF, peripheral blood and 
concentrations of endocannabinoids in brain tissue is not clear yet. Thus, the 
understanding of functional implications of altered levels of endocannabinoids in each 
type of sample of schizophrenic patients remains to be elucidated. 
 
6. Conclusions 
Several evidences suggest the relationship between changes in one or more components 
of the ECS and some of the symptoms that are present in depression, anxiety-related 
disorders and schizophrenia. Indeed, recent human postmortem and in vivo 
neuroimaging studies are providing more knowledge about the implication of the ECS 
in these mental disorders. Most of the findings in depression and anxiety are related to 
the expression and/or functionality of CB1 receptors and FAAH in brain areas 
belonging to the amygdala-hippocampal-cortico-striatal neural circuit, especially the 
frontal cortex in depression and the amygdala in anxiety disorders. Regarding 
schizophrenia, the findings in postmortem and living human brains highlight a 
deregulation of CB1 receptor in specific brain areas that are highly affected in this 




these adaptive changes. However, we must be cautious since peripheral 
endocannabinoid levels may not be well correlated with brain concentrations. 
The pharmacological manipulation of the ECS is envisaged as an attractive alternative 
treatment for these mental disorders. For instance, drugs as the phytocannabinoid 
compound CBD have been reported to be effective to treat schizophrenia.  
The advance in this field, together with the translational preclinical research is opening 
an attractive research scenario for the development of promising new pharmacological 
strategies based on drugs targeting the ECS to treat mental disorders. 
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Table 1. Studies about alterations of the different components of the ECS in the brain of 















































































































































































































































































24:24   
Co-IP/PMBT  Rodríguez-









microarray/ PMBT  
Choi et al., 
(2012) 
↑ increase; ↓ decrease; ≈ no significant change. ACC: anterior cingulate cortex; BA: 
Brodmann area; CB1, CNR1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; Co-
IP: co-immunoprecipitation; Ct: control; DLPC: dorsolateral prefrontal cortex; FAAH: 
fatty acid amide hydrolase; fMRI: functional magnetic resonance image; GM: grey 
matter; HINT-1: histidine triad nucleotide binding protein 1; IHC: immunohistochemistry; 
MDD: major depression disorder; PET: positron emission tomography; PFC: prefrontal 
cortex; PMBT: post-mortem brain tissue; PTSD: posttraumatic stress disorder; SSRI: 





Table 2. Studies about alterations of the different components of the ECS in the brain 





































Ceccarini et al., 
(2013) 
 ↑ (23%) BS/pons 9-10 
In vivo brain PET scan 
[11C]OMAR 
Wong et al., 
(2010) 
CB1  ↑ (8%) DLPC (BA9) 21-21 [
3
H]-OMAR/PMBT 
Volk et al., 
(2014) 




Jenko et al., 
(2012) 






Dalton et al., 
(2011) 
 ≈ STG 8-8 




Deng et al., 
(2007) 
 ↑ (25%) PCC 8-8 [
3
H]CP-55940/PMBT 
Newell et al., 
(2006) 





 ↑ (23%) DLPC (BA9) 14-14 [3H]CP-55940/PMBT 
















DLPC (BA9) 25-25 Immunoblot/PMBT 
Urigüen et al., 
(2009) 
 ↓ (12-14%) DLPC (BA9) 23-23 
Immunohistochemistry 
/PMBT 
Eggan et al., 
(2008) 
 ≈ ACC 15-15 
Immunohistochemistry 
/PMBT 
Koethe et al., 
(2007) 
CB1  ≈ 
DLPC 
(BA46) 
37-37 RT-qPCR/ PMBT 
Dalton et al., 
(2011) 
(mRNA) ≈ DLPC (BA9) 20-20 RT-qPCR/ PMBT 
Urigüen et al., 
(2009) 
 ↓ (15%) DLPC (BA9) 23-23 
In situ hybridization/ 
PMBT 
Eggan et al., 
(2008) 
CB2 (mRNA) ≈ DLPC (BA9) 23-24 RT-qPCR/ PMBT 











DLPC (BA9) 42-42 RT-qPCR/ PMBT 







DLPC (BA9) 42-42 RT-qPCR/ PMBT 
Volk et al., 
(2010) 
 
↑ Increase; ↓ decrease; ≈ no significant change. ABHD6: α-β-hydrolase domain 6; AP-F: 
antipsychotic free; AP-T: antipsychotic treated; BA: Bradman’s area; Ct: controls; 
DAGL: diacylglycerol lipase; EC: endocannabinoid; FAAH: fatty acid amide hydrolase; 
MAGL: monoacylglycerol lipase; RT-qPCR: real-time quantitative polymerase chain 
reaction; Sch: patients with schizophrenia; PET: positron emission tomography; PMBT: 
post-mortem brain tissue. 
Brain regions: ACC, anterior cingulate cortex; AM: amygdala; BS, brain stem; CC: 
cingulate cortex; CD: caudate; DLPC, dorsolateral prefrontal cortex; HC: hippocampus; 
HT: hypothalamus; IFC: inferior frontal cortex; Knack, nucleus acumens; PC, parietal 
cortex; PCC, posterior cingulate cortex; STG, superior temporal gyrus. 
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